Extensive research has been conducted on peptide-based vaccines for breast cancer, and several of them, such as the E75, GP2, and AE37 vaccines against HER2, have exhibited potential clinical efficacy [209, 210]. This evidence concerns the gene ERBB2 and breast cancer.